¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

´ëÇÑÁö¹æ°£¿¬±¸È¸ KNSG NAFLD Symposium 2023: Multidisciplinary Approach We Go Together : 2023-10-14

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 

´ëÇÑÁö¹æ°£¿¬±¸È¸ KNSG NAFLD Symposium 2023: Multidisciplinary Approach We Go Together : 2023-10-14
±³À°ÀÏÀÚ : 2023-10-14
±³À°Àå¼Ò : ½ÅÃ̼¼ºê¶õ½ºº´¿ø ¿¡ºñ½¼ÀÇ»ý¸í¿¬±¸¼¾ÅÍ 1Ãþ À¯ÀÏÇÑȦ

±³À°ÁÖÁ¦ : KNSG NAFLD Symposium 2023: Multidisciplinary Approach We Go Together

ÁÖÃÖ±â°ü : ´ëÇÑ°£ÇÐȸ
½ÃÇà±â°ü(ÁöºÎ/°ú) : ´ëÇÑÁö¹æ°£¿¬±¸È¸

´ã´çÀÚ : ´ëÇÑ°£ÇÐȸ
¿¬¶ôó : 02-707-0091

À̸ÞÀÏ : kasl@kams.or.kr

±³À°Á¾·ù : ³»°ú

Âü¼®¿¹»óÀÎ : 200¸í
Èñ¸ÁÆòÁ¡ : 5Á¡

Áö¿ª : ¼­¿ïƯº°½Ã
±³À°½Ã°£ : 5 ½Ã°£ 20ºÐ

¼¼ºÎ¼ö°­·á : 50,000¿ø  

ºñ°í "»çÀüµî·Ï-ȸ¿ø,ÀüÀÓÀÇ,Àü°øÀÇ 3¸¸¿ø

ºñȸ¿ø,¿Â¶óÀÎȸ¿ø 4¸¸¿ø 

ÇöÀåµî·Ï-ȸ¿ø,ÀüÀÓÀÇ,Àü°øÀÇ 4¸¸¿ø 

ºñȸ¿ø,¿Â¶óÀÎȸ¿ø 5¸¸¿ø"  


±¸ºÐ ¿ùÀÏ °­ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ

±³À°½Ã°£ 10¿ù 14ÀÏ ½ÅÃ̼¼ºê¶õ½ºº´¿ø ¿¡ºñ½¼ÀÇ»ý¸í¿¬±¸¼¾ÅÍ À¯ÀÏÇÑȦ 09:15~09:35 NAFLD and type 2 diabetes ÇÑÀ¯Áø(°è¸íÀÇ´ë)

±³À°½Ã°£ 10¿ù 14ÀÏ ½ÅÃ̼¼ºê¶õ½ºº´¿ø ¿¡ºñ½¼ÀÇ»ý¸í¿¬±¸¼¾ÅÍ À¯ÀÏÇÑȦ 09:35~09:55 NAFLD and chronic kidney disease Á¤Âù¿µ(¿ï»êÀÇ´ë)

±³À°½Ã°£ 10¿ù 14ÀÏ ½ÅÃ̼¼ºê¶õ½ºº´¿ø ¿¡ºñ½¼ÀÇ»ý¸í¿¬±¸¼¾ÅÍ À¯ÀÏÇÑȦ 09:55~10:15 Identification of NAFLD patients with high-risk CVD ÀÌÂùÁÖ(¿¬¼¼ÀÇ´ë)

±³À°½Ã°£ 10¿ù 14ÀÏ ½ÅÃ̼¼ºê¶õ½ºº´¿ø ¿¡ºñ½¼ÀÇ»ý¸í¿¬±¸¼¾ÅÍ À¯ÀÏÇÑȦ 10:15~10:35 NAFLD and obesity: Medical perspective Alice PS KONG(CUHK)

±³À°½Ã°£ 10¿ù 14ÀÏ ½ÅÃ̼¼ºê¶õ½ºº´¿ø ¿¡ºñ½¼ÀÇ»ý¸í¿¬±¸¼¾ÅÍ À¯ÀÏÇÑȦ 10:45~11:05 Sex-dependent NAFLD progression Ayako Suzuki(Duke University)

±³À°½Ã°£ 10¿ù 14ÀÏ ½ÅÃ̼¼ºê¶õ½ºº´¿ø ¿¡ºñ½¼ÀÇ»ý¸í¿¬±¸¼¾ÅÍ À¯ÀÏÇÑȦ 11:05~11:25 Cognitive and behavioral impairments related to NASH Somaya Albhaisi(Virginia Commonwealth University)

±³À°½Ã°£ 10¿ù 14ÀÏ ½ÅÃ̼¼ºê¶õ½ºº´¿ø ¿¡ºñ½¼ÀÇ»ý¸í¿¬±¸¼¾ÅÍ À¯ÀÏÇÑȦ 11:25~11:45 Role of hepatocyte Kctd17 in glucose tolerance and hepatic steatosis ±è°æÁø(ÀÎÇÏÀÇ´ë)

±³À°½Ã°£ 10¿ù 14ÀÏ ½ÅÃ̼¼ºê¶õ½ºº´¿ø ¿¡ºñ½¼ÀÇ»ý¸í¿¬±¸¼¾ÅÍ À¯ÀÏÇÑȦ 11:45~12:05 Tcf7l2 in hepatocytes regulates de novo lipogenesis in NAFLD ¿À°æÁø(KRIBB)

±³À°½Ã°£ 10¿ù 14ÀÏ ½ÅÃ̼¼ºê¶õ½ºº´¿ø ¿¡ºñ½¼ÀÇ»ý¸í¿¬±¸¼¾ÅÍ À¯ÀÏÇÑȦ 12:05~12:25 Roles of portal lipoprotein and immunity as guardians of the liver ÇÑ¿ëÇö(°­¿ø¾à´ë)

±³À°½Ã°£ 10¿ù 14ÀÏ ½ÅÃ̼¼ºê¶õ½ºº´¿ø ¿¡ºñ½¼ÀÇ»ý¸í¿¬±¸¼¾ÅÍ À¯ÀÏÇÑȦ 13:25~13:45 Barriers for successful clinical trials in NASH Stephen A Harrison(Pinnacle Clinical Research, San Antonio)

±³À°½Ã°£ 10¿ù 14ÀÏ ½ÅÃ̼¼ºê¶õ½ºº´¿ø ¿¡ºñ½¼ÀÇ»ý¸í¿¬±¸¼¾ÅÍ À¯ÀÏÇÑȦ 13:45~14:05 Biomarkers for identifying at-risk NASH and monitoring treatment response ±è¿ø(¼­¿ïÀÇ´ë)

±³À°½Ã°£ 10¿ù 14ÀÏ ½ÅÃ̼¼ºê¶õ½ºº´¿ø ¿¡ºñ½¼ÀÇ»ý¸í¿¬±¸¼¾ÅÍ À¯ÀÏÇÑȦ 14:05~14:25 Pharmacotherapeutics in phase II and III clinical trial ¹Ú¼ö¿µ(°æºÏÀÇ´ë)

±³À°½Ã°£ 10¿ù 14ÀÏ ½ÅÃ̼¼ºê¶õ½ºº´¿ø ¿¡ºñ½¼ÀÇ»ý¸í¿¬±¸¼¾ÅÍ À¯ÀÏÇÑȦ 14:35~14:55 Different diets, different outcomes °íÇýÁø(°æºÏÀÇ´ë)

±³À°½Ã°£ 10¿ù 14ÀÏ ½ÅÃ̼¼ºê¶õ½ºº´¿ø ¿¡ºñ½¼ÀÇ»ý¸í¿¬±¸¼¾ÅÍ À¯ÀÏÇÑȦ 14:55~15:15 What types of exercise are beneficial for NAFLD/NASH? ¹ÚÁøÈ£(¼­¿ïÀÇ´ë)

±³À°½Ã°£ 10¿ù 14ÀÏ ½ÅÃ̼¼ºê¶õ½ºº´¿ø ¿¡ºñ½¼ÀÇ»ý¸í¿¬±¸¼¾ÅÍ À¯ÀÏÇÑȦ 15:15~15:35 The potential of 3D food printing technology for application to patients with metabolic diseases ±èÀº°æ(µ¿¾Æ´ëÇб³)

±³À°½Ã°£ 10¿ù 14ÀÏ ½ÅÃ̼¼ºê¶õ½ºº´¿ø ¿¡ºñ½¼ÀÇ»ý¸í¿¬±¸¼¾ÅÍ À¯ÀÏÇÑȦ 15:35~15:55 Novel therapeutic targets in NAFLD treatment in the year of 2023 Àü´ë¿ø(ÇѾçÀÇ´ë)

 

ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" ´ëÇÑÁö¹æ°£¿¬±¸È¸ KNSG NAFLD Symposium 2023: Multidisciplinary Approach We Go Together : 2023-10-14""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û ´ëÇÑÁßȯÀÚÀÇÇÐȸ (¿Â¶óÀÎ) The 14th SCCM¡¯s Multiprofessional Critical Care Review Course in Seoul, 2023 (MCCRC 2023) (2ÀÏÂ÷) : 2023-10-14
´ÙÀ½±Û 2023³â ´ëÇѽÅÀåÇÐȸ ÀüÇØÁú°íÇ÷¾Ð¿¬±¸È¸ ½ÉÆ÷Áö¾ö : 2023-10-14
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
20910 ¼­¿ï 2024³â Á¦14ȸ °¡Å縯´ëÇб³ ÀÇ°ú´ëÇÐ ³»ºÐºñ³»°ú ¿¬¼ö°­Á : 2024-07-07 0 7 2024-05-28
20909 °æ±â ¾ÆÁÖ´ëÇб³º´¿ø Á¤Çü¿Ü°ú 30Áֳ⠱â³ä ½ÉÆ÷Áö¿ò : 2024-07-07 0 10 2024-05-28
20908 ¼­¿ï Á¦19Â÷ ´ëÇѸðÀ¯¼öÀ¯ÀÇÇÐȸ Ãá°èÇмú´ëȸ : 2024-07-07 0 11 2024-05-28
20907 °æ±â Á¦2Â÷ ´ëÇѽŰæ¹æ»ç¼±¼ö¼úÇÐȸ Á¤±âÇмú´ëȸ : 2024-07-06 0 10 2024-05-28
20906 °æ±â Á¦ 5ȸ ¿À»ê½ÃÀÇ»çȸ Çмú´ëȸ : 2024-07-06 0 10 2024-05-28
20905 ¼­¿ï ¼­¿ï¾Æ»êº´¿ø Á¦3ȸ ¾Æ»êµÎ°æºÎ Æ÷·³ : 2024-07-06 0 15 2024-05-28
20904 ¼­¿ï 2024³â Á¦2ȸ °¡Å縯´ëÇб³ ÀºÆò¼º¸ðº´¿ø ¼øȯ±â³»°ú °³¿øÀÇ ¿¬¼ö°­Á : 2024-07-06 0 10 2024-05-28
20903 ¼­¿ï ´ëÇѼÒÈ­±â³»½Ã°æÇÐȸ ENDO 2024 (Day3) : 2024-07-06 0 11 2024-05-28
20902 ¼­¿ï ´ëÇѽŰæÁýÁßÄ¡·áÇÐȸ 2024³â ÇÏ°è NeurocrItical Care Essence (NICE) ¾ÆÄ«µ¥¹Ì : 2024-07-06 0 9 2024-05-28
20901 ¼­¿ï ¼­¿ï´ëÇб³º´¿ø Á¦10ȸ ºÎ½Å¿¬±¸È¸ ½ÉÆ÷Áö¾ö : 2024-07-06 0 3 2024-05-28
20900 ¼­¿ï ´ëÇѼÒÈ­±â³»½Ã°æÇÐȸ ENDO 2024 (Day2) : 2024-07-05 0 5 2024-05-28
20899 ¼­¿ï ÀÓ»ó¼ú±â±³À°¿¬±¸È¸ Á¦16ȸ ÀÓ»ó¼ú±â ¿¬¼ö°­Á : 2024-07-04 0 11 2024-05-28
20898 °æ±â ¿ëÀμ¼ºê¶õ½ºº´¿ø µðÁöÅÐÀÇ·á½ÉÆ÷Áö¾ö -¹Ì·¡ ÀǷḦ À§ÇÑ ±³·ù¿Í Çù·Â : 2024-07-04 0 6 2024-05-28
20897 ¼­¿ï ´ëÇѼÒÈ­±â³»½Ã°æÇÐȸ ENDO 2024 (Day1) : 2024-07-04 0 9 2024-05-28
20896 ¼­¿ï ´ëÇÑ»êºÎÀΰúÇÐȸ ¼­ºÎÁöȸ Á¤±â Áý´ãȸ(Àڱ󻸷Áõ½ÄÁõ) : 2024-07-02 0 8 2024-05-28
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷